I forbindelse med studier af patienter, som fik behandling med PI’ er, observeredes følgende mutationer hos de patienter, der fik virologisk svigt:
In the studies of PI-experienced patients, PRO30017 (amprenavir 600 mg / ritonavir 100 mg twice daily in sub-study A and B with 80 and 37 patients respectively), the following mutations emerged in patients with virological failure: